MAD1L1 (mitotic arrest deficient 1 like 1) is a critical component of the mitotic spindle assembly checkpoint (SAC) that ensures proper chromosome 7 during cell division. The protein functions by interacting with MAD2L1 and other checkpoint proteins to monitor kinetochore attachment and prevent premature anaphase onset 1. Mechanistically, MAD1L1 variants with impaired function show reduced spindle checkpoint activity, leading to decreased mitotic index and 4N-DNA content when cells are treated with microtubule-disrupting agents 1. Loss-of-function mutations in MAD1L1 result in chr7 instability and aneuploidy, hallmarks of cancer development 2. Disease relevance is significant, with mutations identified in various cancers including prostate (2/7 cell lines, 2/33 specimens), lung, lymphoma, and other malignancies 2. A fusion gene RARS-MAD1L1 found in 10% of nasopharyngeal carcinomas promotes tumorigenesis and therapeutic resistance through the FUBP1/c-Myc pathway 3. Clinical significance extends beyond cancer, as MAD1L1 genetic variants are associated with lung cancer susceptibility 1, schizophrenia risk in Han Chinese populations 4, and idiopathic pulmonary fibrosis 5. Additionally, methylation patterns in MAD1L1 correlate with depression severity and suicide attempt phenotypes 6.